LYNN WINGERT: Open Payments
NPI 1992182240 · GETTYSBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$672 in 34 payments from 17 companies in 2025. Trend: 2023 $1,552 · 2024 $1,420 · 2025 $672
Food & beverage: $672
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $106 |
| Astellas Pharma US Inc | 3 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $74 |
| Mannkind Corporation | 2 | $69 |
| GlaxoSmithKline, LLC. | 3 | $51 |
| Lilly USA, LLC | 3 | $49 |
| Merck Sharp & Dohme LLC | 2 | $36 |
| PFIZER INC. | 2 | $32 |
| Seqirus USA Inc | 1 | $29 |
| Amgen Inc. | 1 | $22 |
Products named: Veozah, CAPLYTA, AFREZZA, QULIPTA, VRAYLAR, TRELEGY ELLIPTA, JARDIANCE, MOUNJARO.
Industry payments across PA — which companies pay providers there.
